The CTA spot sign score in acute cerebral hemorrhage (Score-It)

PI: Rosand, Jonathan  
HARVARD MEDICAL SCHOOL  
CENTER FOR HUMAN GENETIC RESEARCH

Detailed Description:

<table>
<thead>
<tr>
<th><strong>Grant Number</strong></th>
<th>R01NS073344</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Study Type</strong></td>
<td>This is an ancillary study of ATACH-2.</td>
</tr>
<tr>
<td><strong>Actual Enrollment</strong></td>
<td>The sample size for the ancillary SCORE-IT study will be determined by the number of subjects enrolled in ATACH-2 and the proportion who undergo the relevant neuroimaging procedures. As of May 12, 2015, 100 sites have enrolled 892 participants into the parent trial. SCORE-IT non-contrast CT arm accrual: 816 SCORE-IT CTA arm accrual: 106 SCORE-IT MRI arm accrual: 208</td>
</tr>
<tr>
<td><strong>Allocation</strong></td>
<td>(Randomized in ATCH-2 to intervention or control arm)</td>
</tr>
<tr>
<td><strong>Intervention Model</strong></td>
<td>Observational</td>
</tr>
<tr>
<td><strong>Primary Purpose</strong></td>
<td>Analyze routinely obtained brain imaging data across the ATCH-2 sites for predictive markers of hematoma expansion and investigate whether these markers can help select the patients most likely to benefit from this intervention.</td>
</tr>
<tr>
<td><strong>Goal</strong></td>
<td>To apply CTA and MRI to identify patients at the highest risk for hematoma expansion to determine whether CTA and MRI can identify patients at high</td>
</tr>
</tbody>
</table>
risk for hematoma growth and whether these imaging techniques can select patients more likely to benefit from early, intensive antihypertensive treatment.

Official Title
SCORE-IT: The CTA Spot Sign Score in Acute Cerebral Hemorrhage

Actual Study Start Date
12/01/2010

Actual Study Completion Date
12/30/2015

Hypothesis and Aim

**Hypothesis 1.** Specific radiographic features obtained from CTA on presentation can identify patients at highest risk for hematoma expansion.

**Specific Aim 1.** To evaluate the Spot Sign Score as a predictor of hematoma expansion across a wide range of centers.

**Hypothesis 2.** The presence of a spot sign identifies individuals who benefit from aggressive blood pressure reduction.

**Specific Aim 2.** To determine whether Spot Sign Score predicts clinical benefit (modified Rankin Score 0-3) received from aggressive blood pressure reduction in the ongoing ATACH-2 clinical trial

**Hypothesis 3.** The underlying vasculopathy responsible for the ICH predicts hematoma expansion.

**Specific Aim 3.** To determine whether the absence of MRI-detectable microbleeds is associated with hematoma expansion and clinical benefit (modified Rankin Score 0-3) received from aggressive blood pressure reduction in the ongoing ATACH-2 clinical trial.

Eligibility Criteria
Enrollment into ATCH-2

Collaborators and Sponsor
Massachusetts General Hospital
Medical University of South Carolina
University of Minnesota
Funding NINDS

As of May 12, 2015, 100 sites have enrolled 892 participants into the parent trial.
Citations

